Editor’s Note: “Every drug can be made, and every disease can be treated”. Over the past 25 years, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision. 

In tribute to the journey and in celebration of new beginnings, we look back through the eyes of our “dream-makers:” revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.

“Yesterday I had a conversation with a client.” Dr. Youchu Wang, Senior Vice President and Head of API Early Phase Development at WuXi AppTec, says. The client hadn’t called to discuss a contract or a particular issue. “Your team is exceptional,” they told him. “You’re professional, you’re fast, you know what needs to be done before I even ask.”

He smiled: “After so many years in this business, I can say with confidence, we really do move faster than most.”

For him, that quiet speed defines the rhythm of his past 17 years of work at WuXi AppTec. 

Building Capability Before the Need

WuXi AppTec’s evolution from early chemistry synthesis to a fully integrated CRDMO reframed the central challenge: translating lab reactions into robust, scalable manufacturing processes. That gap, between the flask and the reactor, is where capability emerges, where teams either improvise or execute by design.

From the outset, Wang has emphasized a distinct mindset, thinking like a process developer. That means mapping synthetic routes with intent, running process R&D with discipline, operating and optimizing equipment deliberately, and drawing conclusions that hold up at scale.

One episode captures this philosophy. The crystallization of a program’s final product began to encounter difficulties: seed crystals refused to form correctly, and the plant was waiting. Wang stepped into the lab himself, repeated the sequence, and produced the correct seed crystals. The root cause turned out to be deceptively subtle: moisture sensitivity. The team re-engineered the operation to isolate every step from air exposure, locked in the crystal form, and delivered the seeds on time. Today, Wang uses this case as a reminder that precision and respect for process are not merely words; they are habits built through daily practice.

That discipline quickly spread across teams. As the number of projects increased, WuXi AppTec paired practical, hands-on work with structured training, helping frontline managers think like developers. The results were clear: operations became smoother, and problems at manufacturing sites almost disappeared.

Much of this capability, Wang noted, was built long before the market demanded it. Clients often remark that WuXi AppTec’s platforms feel years ahead: technologies developed a decade earlier, ready for when the industry caught up. For many new partners, that foresight is what convinces them to collaborate. They’re not merely choosing speed; they’re joining a system engineered in advance to make speed reliable.

Doing it Right the First Time

As WuXi AppTec’s capabilities grew, the focus naturally shifted from building them to proving how they perform under real pressure. The company’s expertise in chemistry and process development became its foundation. The real test was whether that foundation could deliver consistent speed, solve problems effectively, and earn lasting trust from clients.

“True speed,” Wang says, “isn’t about going fast; it’s about getting it right the first time.” Rushing only leads to rework, and rework slows everything down. What really keeps projects moving is foresight: a well-thought-out method, a clear plan everyone can follow, and an initial experiment that produces results you can build on.

That philosophy shows up in everyday work. Processes are designed to reduce variation, and handoffs are practiced to prevent bottlenecks. Early planning may seem slow at first, but it makes the whole project run more smoothly. “Speed,” Wang says, “is what quality looks like over time.” It’s not about chasing deadlines; it’s about removing the causes of delay.

The results speak quietly but clearly. The cycle to complete one step of chemical process development and manufacture that once took four to five weeks now finish in one to two weeks, three at most. Quality deviations are kept to an absolute minimum, a level clients see as proof rather than promise. In manufacturing terms, precision is the engine, and speed follows naturally.

This same disciplined system matters most when projects become complex. Many clients turn to Wang’s team when a program elsewhere has stalled. “In one case,” Wang recalled, “we took over a project that had completely stalled. Within two months, we reset the process and delivered clean results.” Later, the client wrote to thank the team: “Your speed, your quality, and your technical capability made everything smoother and easier for us.”

For Wang, that is the real meaning of speed, not haste, but the ability to move decisively through complexity, to identify what matters, and to make things work when others cannot.

Integration and the Culture That Powers It

If speed is earned through foresight and precision, integration is how that steadiness appears in daily operations. The same discipline that prevents rework also prevents friction between teams. At WuXi AppTec, early- and late-stage programs start aligning months in advance, so handoffs feel less like transfers and more like continuities. Clients, especially smaller or resource-limited biotech companies, see the difference in their schedules and risk profiles: fewer surprises, clearer communication, steadier progress.

One example came from a client who reached out during Christmas week. The program, complex and underperforming elsewhere, was transferred to WuXi AppTec. An early-stage team restarted the work, while late-stage leaders met the client six months before formal transition to align expectations. By the time the handover came, most of the uncertainties had already been resolved. The process continued without interruption, and soon after, the biotech was acquired by a major pharmaceutical company, a reminder that operational continuity can lead to strategic opportunity.

“We are still supporting the program after the acquisition.” Wang adds.

The result is a platform that meets projects where they are and carries them forward without breaking stride. It’s not about claiming perfection; it’s about doing the small, predictable things ensuring that the science keeps moving even as the work changes hands.

On the Road Again

As the call drew to a close, the hum of transit returned. Wang was already between meetings, preparing for the next stop. As he spoke, his tone turned reflective.

“What we’re really building,” he says, “is a strong capability and technology platform, one that enables our partners to develop new drugs both quickly and with high quality, meeting their needs while advancing our broader vision.”

Since joining the company, Wang has seen WuXi AppTec evolve alongside the industry, continually improving and optimizing toward today’s integrated CRDMO model. “We’ve been changing since the beginning,” he noted, “but our focus remains the same: helping move projects toward the market so that people and patients can access better medicines.”

The line went quiet. Somewhere on the road in Europe, Wang continued his trip with the same conviction that shapes his work every day: capability built ahead of need, precision practiced without pause, and a belief that every drug can be made and every disease can be treated.